Semax
A synthetic peptide analog of ACTH(4-10) developed in Russia, studied for cognitive enhancement and neuroprotection.
What is Semax?
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved in Russia as a prescription medication for cognitive and neurological conditions. It is primarily discussed for its potential nootropic (cognitive-enhancing) and neuroprotective properties.
What Semax Is Investigated For
Semax is investigated primarily for cognitive impairment, ischemic stroke recovery, optic nerve disease, and general nootropic use, and the strongest evidence is for post-stroke neurological recovery — the basis for its approval as a prescription medication in Russia and several CIS countries. Supporting preclinical data on BDNF upregulation, neuroprotection in ischemia-reperfusion models, and dopaminergic/serotonergic activation is extensive and mechanistically coherent. The honest caveats mirror Selank's: the clinical literature is heavily Russian-language and connected to the Institute of Molecular Genetics development program, independent Western replication is limited, and controlled trials for off-label nootropic use in healthy adults essentially do not exist. Semax is not FDA-approved, approved Russian courses run only 2–4 weeks so chronic-use safety is uncharacterized, and research-chemical-channel product is not equivalent to the pharmaceutical-grade Geropharm material used in trials.
History & Discovery
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow in the early 1980s, in a program searching for stable, non-hormonally active analogues of ACTH fragments that might retain their reported cognitive and neuroprotective effects without driving the adrenal axis. The team, led by Nikolai Myasoedov and colleagues, designed a heptapeptide corresponding to the 4–10 region of ACTH (methionine-glutamate-histidine-phenylalanine) with a proline-glycine-proline tail appended to resist enzymatic cleavage. That tail is the reason Semax has meaningful half-life when delivered intranasally, where native ACTH fragments would be rapidly degraded. Semax was subsequently registered as a medicine in Russia and is manufactured by Geropharm and other Russian firms, with approved indications including cognitive impairment, ischemic stroke recovery, and optic nerve disease. The clinical literature supporting these indications is almost entirely Russian-language and predominantly published by researchers connected to the development program — a pattern similar to other Soviet and post-Soviet peptide drugs. Outside Russia and a few CIS countries, Semax is not an approved drug. In the Western nootropic community it has been distributed through research-chemical channels and compounding pharmacies since roughly the 2010s, and forum culture around it is robust despite thin English-language clinical evidence.
How It Works
Semax works by increasing levels of brain-derived neurotrophic factor (BDNF), a protein that supports the growth and survival of brain cells. Think of BDNF as fertilizer for your brain — more of it may support better cognitive function, memory, and neural resilience.
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that modulates multiple neurochemical systems. It significantly upregulates BDNF and its receptor TrkB, promoting neuroplasticity and neuronal survival. It modulates serotonergic and dopaminergic systems, enhances expression of neurotrophins NGF and NT-3, and demonstrates anti-inflammatory effects in the CNS. It also affects the expression of genes involved in immune response and vascular function in the brain.
Evidence Snapshot
Human Clinical Evidence
Moderate (primarily Russian literature). Clinical studies in Russia have demonstrated efficacy for cognitive disorders and stroke recovery.
Animal / Preclinical
Strong. Extensive animal data on neuroprotection, BDNF modulation, and cognitive enhancement.
Mechanistic Rationale
Strong. BDNF modulation is a well-established mechanism for cognitive support.
Research Gaps & Open Questions
What the current literature has not yet settled about Semax:
- 01Western, English-language, independently funded human trials — the efficacy literature is heavily Russian and heavily connected to the development program; independent replication in Western clinical contexts is thin.
- 02Long-term safety beyond the 2–4 week windows used in approved Russian protocols — chronic daily use over months or years has not been systematically studied.
- 03Pharmacokinetics and dose-response in diverse populations — most available pharmacokinetic data is in Russian clinical cohorts, and dose-response curves in Western populations with different comorbidity profiles are not well characterized.
- 04Controlled trials for off-label nootropic use in healthy individuals — approved indications are cognitive impairment and stroke; whether Semax produces measurable cognitive enhancement in healthy adults has not been rigorously established in controlled trials.
- 05Pediatric and adolescent safety outside specific approved indications — data is limited to Russian pediatric registrations.
- 06Comparative efficacy vs. other nootropic peptides (Selank, Noopept, Cerebrolysin) and vs. non-peptide cognitive enhancers — head-to-head data is sparse.
Forms & Administration
Semax is most commonly administered intranasally (nasal spray). This route provides direct access to the central nervous system. Protocols should be determined by a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Approved Russian clinical protocols use 0.1% or 1% intranasal solutions delivered at roughly 200–2,000 mcg total per day, divided across nostrils. For general nootropic use in forum-described protocols, 200–600 mcg/day split into 2–3 intranasal doses is the most commonly described range. Higher doses (up to 2,000–3,000 mcg/day) are described in Russian clinical literature for acute stroke or severe cognitive indications, typically under medical supervision.
Frequency
Intranasal dosing is typically split into 2–3 administrations across the day (morning, midday, and optionally afternoon), reflecting Semax's short plasma half-life of roughly 30 minutes and functional effects that appear to outlast plasma presence. Most users describe administering Semax during periods of cognitive demand rather than on a rigid schedule. For neuroprotective indications in Russian clinical use, multiple daily doses are continued across the acute and subacute recovery windows (typically 10–14 days).
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Nootropic users most commonly describe episodic use — during exam periods, demanding work windows, or acute cognitive tasks — rather than chronic daily administration. Episodic use reduces both nasal mucosal irritation and the potential for tachyphylaxis. For approved medical indications, courses are typically 10–14 days for acute stroke and 2–4 weeks for cognitive rehabilitation, with medical guidance on repetition. Continuous daily use beyond several weeks is not well studied and nasal irritation becomes more common.
Protocol Notes
Route matters. Semax was designed for intranasal delivery precisely because the nasal mucosa provides direct access to the CNS via olfactory and trigeminal pathways, bypassing first-pass metabolism and achieving meaningful brain exposure with relatively small doses. Oral, sublingual, and injected formulations are uncommon in the original clinical literature and are not interchangeable with intranasal protocols. Practical administration usually involves 2–3 drops per nostril from a dropper bottle, with the head tilted slightly back and gentle sniffing to distribute across the upper nasal cavity. Spray atomizers deliver more diffusely but less reliably to olfactory mucosa. Nasal irritation — dryness, minor bleeding, or rhinitis — is the most common adverse effect with chronic use. Sourcing is a significant practical concern. Russian pharmaceutical-grade product (typically Geropharm-manufactured Semax 0.1% or 1% solutions) is the reference standard in the clinical literature. Research-chemical-channel Semax varies substantially in purity and actual peptide content.
Semax is not FDA-approved in the United States for any medical indication. It is approved in Russia and some CIS countries under that national regulatory framework. Any use outside approved indications, or outside jurisdictions where it is approved, is not authorized medical care.
Timeline of Effects
Onset
Subjective cognitive effects — improved focus, alertness, mental clarity — are commonly described within 15–60 minutes of an intranasal dose. Measurable effects on mood, motivation, or stress response in clinical and experimental contexts have been reported in similar windows. Neuroprotective effects in stroke contexts are measured over days to weeks of repeated dosing rather than acutely.
Peak Effect
Peak subjective effect is typically described within 1–3 hours of administration. Plasma half-life is short (around 30 minutes) but downstream CNS effects — BDNF upregulation, neuroplasticity-related changes — appear to persist meaningfully longer than the peptide itself. Cumulative benefit in chronic clinical protocols is typically assessed at 10–14 days (acute stroke) or 2–4 weeks (cognitive rehabilitation).
After Discontinuation
Acute effects (focus, alertness) fade within hours of the last dose, consistent with clearance of the peptide. Longer-term changes attributable to accumulated BDNF-mediated signaling may persist for days to weeks after cessation. No documented withdrawal syndrome or rebound cognitive decline has been described in the clinical literature.
Common Questions
Who Semax Is NOT For
- •Pregnancy — no controlled safety data; the approved Russian product labeling lists pregnancy as a contraindication.
- •Breastfeeding — no data on transfer into breast milk; generally avoided.
- •Known hypersensitivity to Semax or to components of the intranasal vehicle (benzalkonium chloride preservative in some formulations).
- •Acute psychotic disorders — because Semax modulates dopaminergic and serotonergic systems, use in active psychosis is generally avoided pending better data.
- •Severe nasal mucosal disease, chronic rhinitis, or recent nasal surgery — intranasal delivery may be poorly tolerated or disrupted in these contexts.
- •Pediatric use outside specific approved Russian indications — safety data in children is limited to specific registered pediatric use-cases in Russia.
Drug & Supplement Interactions
Documented clinical drug interactions for Semax are limited. The most plausible theoretical interactions involve other CNS-active agents. Because Semax modulates dopaminergic and serotonergic systems, concurrent use with potent serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans) or strong dopaminergic agents (stimulants, dopamine agonists) could in principle shift the pharmacologic balance — though no specific adverse interaction has been rigorously documented in published trials. Combining with other nootropic peptides (Selank, Cerebrolysin) is common in Russian clinical practice and in forum culture, but these combinations have not been studied for additive safety endpoints. Semax's short plasma half-life and small doses reduce the likelihood of pharmacokinetic interactions via CYP enzymes or protein binding. There is no documented concern with typical cardiovascular medications, oral hypoglycemics, or anticoagulants. Nasal mucosal decongestants used concurrently may affect intranasal absorption and should typically be separated in time. Patients on any regular psychiatric medication should disclose Semax use to their prescribing clinician, as clinical experience in Western psychiatric populations is essentially absent.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved in the US
- • Most clinical data from Russian studies
- • Should not be used by those with certain hormonal conditions
What We Don't Know
Western clinical trial data is limited. Long-term cognitive effects and optimal duration of use require further study.
Legal Status
United States
Semax is not FDA-approved for any medical indication and is not a controlled substance. It is not a recognized dietary supplement or cosmetic ingredient. US regulatory posture changed meaningfully in April 2026: on April 15, 2026, HHS Secretary Kennedy directed the FDA to remove Semax from Category 2 (bulk drug substances presenting significant safety risks), effective April 22, 2026. Semax has been referred to the Pharmacy Compounding Advisory Committee (PCAC) for review at the July 23–24, 2026 meeting — specifically for the indications of cerebral ischemia, migraine, and trigeminal neuralgia. Removal from Category 2 is not authorization to compound, and any addition to the 503A Bulks List would require further notice-and-comment rulemaking. As of April 2026, Semax is sold in the US primarily through research-chemical suppliers (not authorized for human use) and in limited compounding-pharmacy channels under an ambiguous legal status that may clarify after the July PCAC decision.
International
Approved as a prescription medicine in Russia (registered by Geropharm and other manufacturers) and in several CIS countries including Belarus, Kazakhstan, and Ukraine for cognitive disorders, stroke recovery, and optic nerve disease. Not approved by EMA, MHRA, TGA, or Health Canada; regulatory status across the EU and UK ranges from research-chemical availability to active enforcement against unapproved sale depending on jurisdiction.
Sports & Competition
Semax is not currently listed by name on the WADA Prohibited List. However, WADA's S0 category prohibits any substance 'not approved by any governmental regulatory health authority for human therapeutic use' — a description that does not strictly apply to Semax (which is approved in Russia) but that governing bodies may still invoke in ambiguous cases. Athletes subject to WADA code should not assume Semax is safe to use in competition; when in doubt, consult the relevant national anti-doping authority before use.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Semax is FDA-approved.
Reality
Semax is not FDA-approved for any indication in the United States. It is approved as a prescription drug in Russia and several CIS countries under their national regulatory frameworks. Western availability in the US has been via research-chemical channels and, in some cases, compounding — neither of which is the same as FDA approval.
Myth
Because Semax is derived from ACTH, it affects cortisol and the stress axis like ACTH does.
Reality
Semax was specifically designed as a non-hormonally active analogue. The proline-glycine-proline tail protects it from proteolysis, and the truncation removes the steroidogenic activity of full-length ACTH. Semax does not meaningfully activate the adrenal axis or raise cortisol — that is the point of the molecular design.
Myth
Semax is a stimulant like Adderall or Modafinil.
Reality
Semax modulates dopaminergic and serotonergic systems and upregulates BDNF, but it is not a catecholamine releaser, reuptake inhibitor, or classical stimulant. Subjective effects are typically described as improved focus and clarity rather than the pronounced arousal and appetite suppression of traditional stimulants. Mechanism and subjective profile are distinct categories.
Myth
Semax is safe indefinitely because it is a 'natural' peptide derived from a hormone in the body.
Reality
Semax is a synthetic heptapeptide, not a substance the body produces. Its specific sequence and proline-tail modifications do not occur naturally. Long-term continuous-use safety in humans has not been established; episodic use is the pattern that matches both the approved clinical literature and the absence of chronic-use data.
Myth
All Semax products on the market are equivalent to the pharmaceutical Russian product.
Reality
Research-chemical-channel Semax varies substantially in purity, actual peptide content, and preservative systems. The clinical literature is based on pharmaceutical-grade Russian product (e.g., Geropharm). Unverified sources cannot be assumed to deliver comparable dose or safety.
Published Research
31 studiesThe Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Preclinical study showing Semax and its derivatives corrected cognitive and pathological impairments in an Alzheimer's disease mouse model, with improvements in memory, reduced amyloid burden, and neuroprotective effects linked to BDNF upregulation.
The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing
Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress
Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models
Brain Protein Expression Profile Confirms the Protective Effect of the ACTH((4-7))PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion
Proteomics study confirming Semax's neuroprotective mechanism in cerebral ischemia-reperfusion, identifying specific protein expression changes in anti-apoptotic, anti-inflammatory, and neuroplasticity pathways that explain its stroke recovery benefits.
[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain]
Morphofunctional State of the Large Intestine in Rats under Conditions of Restraint Stress and Administration of Peptide ACTH((4-7))-PGP (Semax)
Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats
Peptide ACTH(4-7)-PGP: Effects on Various Types of Pain and Pain-Induced Behavior in Rats after Systemic and Central Administration
Composition of Colon Microbiota in Rats Treated with ACTH(4-7)-PGP Peptide (Semax) under Conditions of Restraint Stress
Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats
Functional Connectomic Approach to Studying Selank and Semax Effects
Experimental Substantiation of Application of Semax as a Modulator of Immune Reaction on the Model of "Social" Stress
Effects of Semax on the Default Mode Network of the Brain
The efficacy of semax in the treatment of patients at different stages of ischemic stroke
Clinical study demonstrating that Semax improved neurological recovery rates across different stages of ischemic stroke, providing key human efficacy data supporting its approved use in Russia for stroke rehabilitation.
Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism
Semax, an analog of ACTH((4-7)), regulates expression of immune response genes during ischemic brain injury in rats
Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties
Semax prevents learning and memory inhibition by heavy metals
Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity
[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]
Comparison of anticoagulant effects of regulatory proline-containing oligopeptides
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
Foundational mechanistic study demonstrating that Semax activates both dopaminergic and serotonergic systems in the rodent brain, providing the neurochemical basis for its cognitive-enhancing and mood-modulating effects.
[Neonatal Semax and saline injections induce open-field behavior changes in mice of different genotypes]
Comparative study of modulatory effects of Semax and primary proline-containing peptides on hemostatic reactions
[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]
Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease
[A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]
Popular Stacks Including Semax
Quick Facts
- Class
- Nootropic Peptide
- Tier
- C
- Evidence
- Emerging
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 31PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.